We studied the effects of CGP 35348, a centrally active blocker of GABAB receptors, on scopolamine-induced amnesia for a passive avoidance response in the mouse. Both pre-training or post-training intraperitoneal administration of the GABAB antagonist (75, 150 and 300 mg/kg i.p.) significantly reduces the amnesic effect of scopolamine (1.0 mg/kg i.p.). Our results are in agreement with previous observations indicating a role for the GABAB receptors in the modulation of memory function, and suggest a possible role of GABAB receptor antagonists as nootropic drugs.